TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
Portfolio Pulse from
TC BioPharm partners with CareDx to use AlloCell for pharmacokinetic monitoring in the ACHIEVE clinical trial, focusing on allogeneic gamma-delta T cell therapies for AML and MDS.
December 11, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CareDx partners with TC BioPharm to provide AlloCell for pharmacokinetic analysis in the ACHIEVE trial, supporting the development of TCB008 therapy for AML and MDS.
CareDx's involvement in the ACHIEVE trial through its AlloCell solution could enhance its reputation and demand for its pharmacokinetic analysis services, potentially benefiting its business operations.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
TC BioPharm partners with CareDx to enhance the ACHIEVE clinical trial using AlloCell for monitoring TCB008 therapy, potentially advancing treatment for AML and MDS.
The partnership with CareDx to use AlloCell in the ACHIEVE trial could enhance the development and effectiveness of TCB008 therapy, potentially leading to positive outcomes for TC BioPharm's clinical advancements.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90